Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Madan Jagasia, MD MS, Amandeep Salhotra, MD, Carlos R. Bachier, MD, James Essell, MD, Daniel J. Weisdorf, MD, Behyar Zoghi, MD PhD, Laurie S. Green, MD, Olivier Schueller, PhD, Alexandra Zanin-Zhorov, PhD, Jonathan M. Weiss, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 602.

https://doi.org/10.1182/blood-2018-99-111896

Published: 2018

Journal Articles

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Madan Jagasia, MD MS, Miguel-Angel Perales, MD, Mark A Schroeder, MD, Haris Ali, MD, Nirav N Shah, MD, Yi-Bin Chen, MD, Michael C. Arbushites, Fitzroy Dawkins, MD, Chuan Tian, PhD, Hanna Jean Khoury, MD FACP

Blood (2018) 132 (Supplement 1): 601.

https://doi.org/10.1182/blood-2018-99-116342

Published: 2018

Journal Articles

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Robert Frank Cornell, MD, Samuel Z. Goldhaber, MD, Brian G Engelhardt, MD, Javid Moslehi, MD, Madan Jagasia, MD MS, Daryl Patton, Shelton Lacy Harrell, MSN, Robert L Hall, MSN, Houston Wyatt, PharmD, Gregory Piazza, MD

Blood (2018) 132 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2018-99-112577

Published: 2018

Journal Articles

Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Jaap Jan Boelens, MD PhD, Coco de Koning, Mitchell E. Horwitz, MD, Guillermo Sanz, Madan Jagasia, MD MS, John E. Wagner, MD, Patrick J. Stiff, MD, Rabi Hanna, MD, Daniela Cilloni, MD PhD, Stefan Nierkens, PhD

Blood (2018) 132 (Supplement 1): 2123.

https://doi.org/10.1182/blood-2018-99-116700

Published: 2018

Journal Articles

Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study

Rohini Radia, MD FRCPath, Arun Alfred, Matthew P. Collin, MD PhD, Maria H Gilleece, MD FRCPath, MB, BSc, FRCP, James E Griffin, BSc (Hons), MBChB (Hons), PhD, Ann E. Hunter, MBBS, FRCP, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Harpreet Kaur, Nandita Khera, MD, Kavita Raj, MD PhD, Emma Das-Gupta, DM, FRCPath, MRCP, Fiona Louise Dignan, MD, Madan Jagasia, MD MS

Blood (2018) 132 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2018-99-115376

Published: 2018

Journal Articles

A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)

Mark A. Schroeder, MD, H. Jean Khoury, MD FACP, Madan Jagasia, MD MS, Haris Ali, MD, Gary J. Schiller, MD, Michael Arbushites, Patricia Delaite, Ying Yan, Kathleen Rhein, Miguel-Angel Perales, MD, Yi-Bin Chen, MD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 390.

https://doi.org/10.1182/blood.V128.22.390.390

Published: 2016

Journal Articles

Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response

Jeanne Palmer, MD, Stephanie J. Lee, MD, MPH, Xiaoyu Chai, MS, Barry Storer, PhD, Joseph Pidala, MD, MS, Corey S. Cutler, MD, MPH, FRCPC, Mukta Arora, MD, Mary E.D. Flowers, MD, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Yoshihiro Inamoto, MD, Madan Jagasia, MD, MS, Chen George, MD, Paul J. Martin, MD

Blood (2011) 118 (21): 1978.

https://doi.org/10.1182/blood.V118.21.1978.1978

Published: 2011

Journal Articles

Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR

Blood (2010) 116 (21): 897.

https://doi.org/10.1182/blood.V116.21.897.897

Published: 2010

Journal Articles

Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium

Joseph Pidala, MD, MS, Brenda Kurland, PhD, Shawn Chai, Navneet S. Majhail, MD, MS, Daniel J. Weisdorf, MD, Corey Cutler, MD, MPH, FRCPC, Madan Jagasia, MD, MS, Jeanne Palmer, MD, Mukta Arora, MD, Paul J. Martin, David Jacobsohn, MD, Georgia B. Vogelsang, MD, Steven Z. Pavletic, MD, Stephanie J. Lee

Blood (2010) 116 (21): 393.

https://doi.org/10.1182/blood.V116.21.393.393

Published: 2010

Journal Articles

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Sally Arai, MD, Madan Jagasia, MD, MS, Mukta Arora, MD, David Miklos, MD, PhD, Xiaoyu Chai, MS, Barry Storer, PhD, Paul J. Martin, Corey Cutler, MD, MPH, FRCPC, Daniel J. Weisdorf, MD, Joseph Pidala, Jeanne Palmer, MD, Mary Flowers, MD, David Jacobsohn, MD, Paul A. Carpenter, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Stephanie J. Lee

Blood (2010) 116 (21): 220.

https://doi.org/10.1182/blood.V116.21.220.220

Published: 2010

Journal Articles

Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT

William Clark, MD, Dana Crawford, Ph.D, Brian Engelhardt, MD, MS, Kristin D. Brown, Fan Kang-Hsien, PhD, Heidi Chen, PhD, Bipin N. Savani, MD, Friedrich Schuening, MD, John P. Greer, MD, Adetola A. Kassim, MD, MS, Madan Jagasia, MD, MS

Blood (2010) 116 (21): 215.

https://doi.org/10.1182/blood.V116.21.215.215

Published: 2010

Journal Articles

Quantitative Assessment of Myeloid Nuclear Differentiation Antigen Distinguishes Myelodysplastic Syndrome From Normal Bone Marrow.

Head R. Head, MD, Sara A. McClintock-Treep, MD, Leanne flye-Blakemore, M.S., Claudio Mosse, MD, PhD, Madan Jagasia, MD, MS, Andrew Shinar, MD, William D Dupont, PhD, Greg Stelzer, PhD, Robert Briggs, PhD, Keith E Shults, BS

Blood (2009) 114 (22): 1754.

https://doi.org/10.1182/blood.V114.22.1754.1754

Published: 2009

Journal Articles

Impact of Early Lymphocyte Recovery On Transplant Outcome After Cord Blood Transplantation.

Sara K Tedeschi, Brian Engelhardt, MD, Waleed Khalaf, Janice Tracy, Jennifer Domm, Wichai Chinratanalab, Adetola A. Kassim, MD, MS, Stacey Goodman, MD, John P. Greer, MD, Friedrich Schuening, MD, Madan Jagasia, MD, MS, Haydar Frangoul, MD, Bipin N. Savani, MD

Blood (2009) 114 (22): 3386.

https://doi.org/10.1182/blood.V114.22.3386.3386

Published: 2009

Journal Articles

Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome.

Daniel G Stover, MD, Vishruth K Reddy, John P. Greer, MD, Madan Jagasia, MD, MS, David Morgan, MD, Brian Engelhardt, MD, Adetola A. Kassim, MD, MS, Stacey Goodman, MD, Carole Hunt, Friedrich Schuening, MD, Bipin N. Savani, MD, Nishitha Reddy, MD

Blood (2009) 114 (22): 3407.

https://doi.org/10.1182/blood.V114.22.3407.3407

Published: 2009

Journal Articles

Vaccinations Efficacy in Long Term Survivors After Allogeneic Stem Cell Transplantation: Implication of Repeat Vaccinations and Documenting Vaccination Efficacy.

Carey Clifton, Leigh Ann Vaughan, Catherine Lucid, Sharon Sims, Brian Engelhardt, MD, Wichai Chinratanalab, MD, Adetola A. Kassim, MD, MS, Stacey Goodman, MD, John P. Greer, MD, Friedrich Schuening, MD, Madan Jagasia, MD, MS, Bipin N. Savani, MD

Blood (2009) 114 (22): 3330.

https://doi.org/10.1182/blood.V114.22.3330.3330

Published: 2009

Journal Articles

SNX 2112, An Oral Hsp-90 Inhibitor Exerts Antiproliferative Effects in Combination with Bortezomib and Rituximab in Rituximab Resistant Non-Hodgkin's Lymphoma.

Nishitha Reddy, MD, Donna Hicks, BS, Madan Jagasia, MD, MS, Kathy Amiri, PhD

Blood (2009) 114 (22): 3733.

https://doi.org/10.1182/blood.V114.22.3733.3733

Published: 2009

Journal Articles

Pharmacoeconomics of Stem Cell Mobilization Using Cyclophosphamide and G-Csf.

Madan Jagasia, MD, MS, Heidi Chen, PhD, Sheri Dixon, Jodene Hume-Rowland, Bipin N. Savani, MD, Anne T. Neff, MD, Kimberely Moyers, Wichai Chinratanalab, MD, Friedrich Schuening, MD

Blood (2009) 114 (22): 4526.

https://doi.org/10.1182/blood.V114.22.4526.4526

Published: 2009

Journal Articles

α 4 β 7 ± Regulatory T Cells (Tregs) at Engraftment Predict Long-Term Graft-Versus-Host Disease (GVHD) Outcomes.

Brian G Engelhardt, MD, MS, Madan Jagasia, MD, MS, Michael T Rock, PhD, Adetola A. Kassim, MD, MS, Bipin N. Savani, MD, Friedrich Schuening, MD, James E Crowe, Jr., MD

Blood (2009) 114 (22): 2237.

https://doi.org/10.1182/blood.V114.22.2237.2237

Published: 2009

Journal Articles

Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).

David Jacobsohn, MD, ScM, Xiaoyu Chai, MS, Brenda Kurland, PhD, Sally Arai, MD, Mukta Arora, MD, MS, Corey Cutler, MD, MPH, Madan Jagasia, MD, MS, Steven Z. Pavletic, MD, Georgia Vogelsang, Stephanie J. Lee, MD, MPH, Mary E.D. Flowers, MD

Blood (2009) 114 (22): 2256.

https://doi.org/10.1182/blood.V114.22.2256.2256

Published: 2009

Journal Articles

Circulating Gut- or Skin-Homing Regulatory T Cells (Tregs) Predict Whether Acute Graft-Versus-Host Disease (aGVHD) Occurs in Gut or Skin Following Allogeneic Stem Cell Transplantation (ASCT)

Brian Engelhardt, MD, Madan Jagasia, MD, MS, Michael T Rock, PhD, Nikki L Bratcher, BS, John P. Greer, MD, Aixiang Jiang, MS, Adetola A. Kassim, MD, MS, Pengcheng Lu, MS, Friedrich Schuening, MD, James E Crowe, Jr., MD

Blood (2008) 112 (11): 717.

https://doi.org/10.1182/blood.V112.11.717.717

Published: 2008

NARROW

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study

A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)

Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response

Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR

Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT

Quantitative Assessment of Myeloid Nuclear Differentiation Antigen Distinguishes Myelodysplastic Syndrome From Normal Bone Marrow.

Impact of Early Lymphocyte Recovery On Transplant Outcome After Cord Blood Transplantation.

Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome.

Vaccinations Efficacy in Long Term Survivors After Allogeneic Stem Cell Transplantation: Implication of Repeat Vaccinations and Documenting Vaccination Efficacy.

SNX 2112, An Oral Hsp-90 Inhibitor Exerts Antiproliferative Effects in Combination with Bortezomib and Rituximab in Rituximab Resistant Non-Hodgkin's Lymphoma.

Pharmacoeconomics of Stem Cell Mobilization Using Cyclophosphamide and G-Csf.

α 4 β 7 ± Regulatory T Cells (Tregs) at Engraftment Predict Long-Term Graft-Versus-Host Disease (GVHD) Outcomes.

Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).

Circulating Gut- or Skin-Homing Regulatory T Cells (Tregs) Predict Whether Acute Graft-Versus-Host Disease (aGVHD) Occurs in Gut or Skin Following Allogeneic Stem Cell Transplantation (ASCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only